SCIENTIFIC REPORTS

OPEN

Corrigendum: Recurrent hormone-binding domain truncated *ESR1* amplifications in primary endometrial cancers suggest their implication in hormone independent growth

Frederik Holst, Erling A. Hoivik, William J. Gibson, Amaro Taylor-Weiner, Steven E. Schumacher, Yan W. Asmann, Patrick Grossmann, Jone Trovik, Brian M. Necela, E. Aubrey Thompson, Matthew Meyerson, Rameen Beroukhi, Helga B. Salvesen & Andrew D. Cherniack

Scientific Reports 6:25521; doi: 10.1038/srep25521; published online 10 May 2016; updated on 30 June 2017

This Article contains errors in the frequencies of *ESR1* amplifications concerning uterine corpus endometrioid carcinoma (UCEC) in TCGA, which were incorrectly given as 88 cases (16.3%) and 36 cases (6.7%) for overall and focal amplifications respectively. These numbers represent the regarding amplification frequencies of partial *ESR1* sequences that manifest the GISTIC peak.

The correct frequencies of *ESR1* amplification in UCEC of TCGA are 90 cases (16.7%) and 39 cases (7.2%) for overall and focal amplification respectively. Accordingly, the seven cases with *ESR1* amplifications that appear to truncate the hormone-binding domain encoding region manifest 17.9% instead of 19.4% of cases with focal amplification.

In addition, the GISTIC q-value for *ESR1* amplification is incorrectly given as “ $q = 5.75 \times 10^{-4}$ ”. The correct term and number for this value is “residual $q = 2.29 \times 10^{-4}$ after ‘GISTIC peel-off’”.

As a result, in the Results section under subheading ‘Hormone-binding domain truncated *ESR1* amplifications in primary endometrial cancers’.

“In the TCGA data subset of 539 endometrial carcinomas analyzed, we identified 88 (16.3%) cases with amplifications encompassing or overlapping *ESR1*. 46.6% of these were histologically defined serous and 75.0% of the tumors with *ESR1* amplification were clustered within the serous like copy-number high molecular subtype according to TCGA. The *ESR1* amplifications were focal (less than half a chromosome arm in length) in 36 cases (6.7%) of tumors, and had a significantly higher rate of amplification than the genome-wide average ($q = 5.75 \times 10^{-4}$). Mapping of the overlap between amplifications across tumors identified *ESR1* only as the most likely gene target (see methods).

These amplifications appeared to truncate the hormone-binding domain encoding region in seven cases (1.3% of the entire dataset; and 19.4% of cases with focal *ESR1* amplification) and to retain exons 1–4 or 1–3, encoding the n-terminal *ESR1* transactivation domain (AF1) and DNA-binding domains. Another case without *ESR1* amplification exhibited a heterozygous deletion of exons encoding the hormone-binding domain (Fig. 2), for a total apparent *ESR1* truncation rate of 1.5% over all tumors. In one additional TCGA case, we detected a hormone-binding domain (exons 4–8) truncating *ESR1*-*SYNE1* mRNA fusion (Appendix B). Eight of these

nine tumors were molecularly classified as being in the serous like copy-number high subgroup (4.3% of this subgroup)."

should read:

"In the TCGA data subset of 539 endometrial carcinomas analyzed, we identified 90 (16.7%) cases with amplifications encompassing or overlapping *ESR1*. 45.6% of these were histologically defined serous and 75.0% of the tumors with *ESR1* amplification were clustered within the serous like copy-number high molecular subtype according to TCGA. The *ESR1* amplifications were focal (less than half a chromosome arm in length) in 39 cases (7.2%), and had a significantly higher rate of amplification than the genome-wide average (residual $q = 2.29 \times 10^{-4}$ after "GISTIC peel-off"). Mapping of the overlap between amplifications across tumors identified *ESR1* only as the most likely gene target (see methods).

These amplifications appeared to truncate the hormone-binding domain encoding region in seven cases (1.3% of the entire dataset; and 17.9% of cases with focal *ESR1* amplification) and to retain exons 1–4 or 1–3, encoding the n-terminal *ESR1* transactivation domain (AF1) and DNA-binding domains. Another case without *ESR1* amplification exhibited a heterozygous deletion of exons encoding the hormone-binding domain (Fig. 2), for a total apparent *ESR1* truncation rate of 1.5% over all tumors. In one additional TCGA case, we detected a hormone-binding domain (exons 4–8) truncating *ESR1-SYNE1* mRNA fusion (Appendix B). Eight of these nine tumors were molecularly classified as being in the serous like copy-number high subgroup (4.3% of this subgroup)."

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017